Skip to main content
SpringerLink
Log in

NK and MSCs Crosstalk: The Sense of Immunomodulation and Their Sensitivity

  • Published:
Stem Cell Reviews and Reports Aims and scope Submit manuscript

Abstract

Several clinical trials are currently evaluating the safety and efficacy of mesenchymal stem cells (MSCs) in different diseases. The MSCs are guided by inflammatory mediators and specific interactions with immune cells occur, especially between MSCs and the cells of the innate immune system. At the present many of these interactions remain to be determined. This review summarizes the current knowledge in relation to the susceptibility of MSCs to NK cell mediated lysis as well as the immunomodulatory activity of MSCs and its control over NK cell function. Here we hypothesize that the inflammatory context will regulate the outcome of NK-MSC interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chen, X., Armstrong, M. A., & Li, G. (2006). Mesenchymal stem cells in immunoregulation. Immunology and Cell Biology, 84(5), 413–421.

    Article  PubMed  CAS  Google Scholar 

  2. Stagg, J. (2007). Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens, 69(1), 1–9.

    Article  PubMed  CAS  Google Scholar 

  3. Shi, Y., Su, J., Roberts, A. I., et al. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends in Immunology, 33(3), 136–143.

    Article  PubMed  CAS  Google Scholar 

  4. English, K., & Mahon, B. P. (2011). Allogeneic mesenchymal stem cells: agents of immune modulation. Journal of Cellular Biochemistry, 112(8), 1963–1968.

    Article  PubMed  CAS  Google Scholar 

  5. Zhao, S., Wehner, R., Bornhauser, M., et al. (2010). Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells and Development, 19(5), 607–614.

    Article  PubMed  CAS  Google Scholar 

  6. Gebler, A., Zabel, O., & Seliger, B. (2011). The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine, 18(2), 128–134.

    Article  PubMed  Google Scholar 

  7. Rasmusson, I., Uhlin, M., Le, B. K., & Levitsky, V. (2007). Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. Journal of Leukocyte Biology, 82(4), 887–893.

    Article  PubMed  CAS  Google Scholar 

  8. Chen, L., Zhang, W., Yue, H., et al. (2007). Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells and Development, 16(5), 719–731.

    Article  PubMed  CAS  Google Scholar 

  9. Ramasamy, R., Fazekasova, H., Lam, E. W., et al. (2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation, 83(1), 71–76.

    Article  PubMed  Google Scholar 

  10. Prigione, I., Benvenuto, F., Bocca, P., et al. (2009). Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells, 27(3), 693–702.

    Article  PubMed  CAS  Google Scholar 

  11. Chen, L., Tredget, E. E., Wu, P. Y., & Wu, Y. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One, 3(4), e1886.

    Article  PubMed  Google Scholar 

  12. Krasnodembskaya, A., Samarani, G., Song, Y., et al. (2012). Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. American Journal of Physiology. Lung Cellular and Molecular Physiology, 302(10), L1003–L1013.

    Article  PubMed  CAS  Google Scholar 

  13. Tu, Z., Li, Q., Bu, H., & Lin, F. (2010). Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells and Development, 19(11), 1803–1809.

    Article  PubMed  CAS  Google Scholar 

  14. Yagi, H., Soto-Gutierrez, A., Parekkadan, B., et al. (2010). Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplantation, 19(6), 667–679.

    Article  PubMed  Google Scholar 

  15. Deak, E., Seifried, E., & Henschler, R. (2010). Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. International Reviews of Immunology, 29(5), 514–529.

    Article  PubMed  CAS  Google Scholar 

  16. Rasmusson, I., Ringden, O., Sundberg, B., & Le, B. K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76(8), 1208–1213.

    Article  PubMed  Google Scholar 

  17. Gotherstrom, C., Lundqvist, A., Duprez, I. R., et al. (2011). Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy, 13(3), 269–278.

    Article  PubMed  Google Scholar 

  18. Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24(1), 74–85.

    Article  PubMed  Google Scholar 

  19. Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107(4), 1484–1490.

    Article  PubMed  CAS  Google Scholar 

  20. Poggi, A., Prevosto, C., Massaro, A. M., et al. (2005). Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. Journal of Immunology, 175(10), 6352–6360.

    CAS  Google Scholar 

  21. Karre, K. (2008). Natural killer cell recognition of missing self. Nature Immunology, 9(5), 477–480.

    Article  PubMed  Google Scholar 

  22. DelaRosa, O., Sanchez-Correa, B., Morgado, S., et al. (2011). Human adipose-derived stem cells impair NK cell function and exhibit low susceptibility to NK-mediated lysis. Stem Cells and Development, 21(8), 1333–1343.

    Article  PubMed  Google Scholar 

  23. El, H. N., Moore, R., Heathcote, D., et al. (2011). The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells. Journal of Immunology, 187(5), 2252–2260.

    Article  Google Scholar 

  24. Hoogduijn, M. J., Roemeling-van, R. M., Korevaar, S. S., et al. (2011). Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies. Human Gene Therapy, 22(12), 1587–1591.

    Article  PubMed  CAS  Google Scholar 

  25. Bartholomew, A., Sturgeon, C., Siatskas, M., et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology, 30(1), 42–48.

    Article  PubMed  Google Scholar 

  26. Noort, W. A., Kruisselbrink, A. B., in’t Anker PS, et al. (2002). Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Experimental Hematology, 30(8), 870–878.

    Article  PubMed  Google Scholar 

  27. Barry, F. P. (2003). Biology and clinical applications of mesenchymal stem cells. Birth Defects Research. Part C, Embryo Today, 69(3), 250–256.

    Article  CAS  Google Scholar 

  28. Jorgensen, C., Djouad, F., Apparailly, F., & Noel, D. (2003). Engineering mesenchymal stem cells for immunotherapy. Gene Therapy, 10(10), 928–931.

    Article  PubMed  CAS  Google Scholar 

  29. Le, B. K. (2003). Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy, 5(6), 485–489.

    Article  Google Scholar 

  30. Ghannam, S., Pene, J., Torcy-Moquet, G., Jorgensen, C., & Yssel, H. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Journal of Immunology, 185(1), 302–312.

    Article  CAS  Google Scholar 

  31. Zheng, Z. H., Li, X. Y., Ding, J., Jia, J. F., & Zhu, P. (2008). Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford, England), 47(1), 22–30.

    Article  CAS  Google Scholar 

  32. Gonzalez-Rey, E., Gonzalez, M. A., Varela, N., et al. (2010). Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Annals of the Rheumatic Diseases, 69(1), 241–248.

    Article  PubMed  CAS  Google Scholar 

  33. Gonzalez-Rey, E., Anderson, P., Gonzalez, M. A., et al. (2009). Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut, 58(7), 929–939.

    Article  PubMed  CAS  Google Scholar 

  34. Rasmusson, I., Le, B. K., Sundberg, B., & Ringden, O. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scandinavian Journal of Immunology, 65(4), 336–343.

    Article  PubMed  CAS  Google Scholar 

  35. Svobodova, E., Krulova, M., Zajicova, A., et al. (2012). The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells and Development, 21(6), 901–910.

    Article  PubMed  CAS  Google Scholar 

  36. Spaggiari, G. M., Abdelrazik, H., Becchetti, F., & Moretta, L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113(26), 6576–6583.

    Article  PubMed  CAS  Google Scholar 

  37. Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815–1822.

    Article  PubMed  CAS  Google Scholar 

  38. Krampera, M., Cosmi, L., Angeli, R., et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2), 386–398.

    Article  PubMed  CAS  Google Scholar 

  39. Yakar, I., Melamed, R., Shakhar, G., et al. (2003). Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Annals of Surgical Oncology, 10(4), 469–479.

    Article  PubMed  Google Scholar 

  40. Chen, Y., Perussia, B., & Campbell, K. S. (2007). Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. Journal of Immunology, 179(5), 2766–2773.

    CAS  Google Scholar 

  41. Torres, D., Paget, C., Fontaine, J., et al. (2008). Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. Journal of Immunology, 180(2), 783–792.

    CAS  Google Scholar 

  42. Giuliani, M., Oudrhiri, N., Noman, Z. M., et al. (2011). Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood, 118(12), 3254–3262.

    Article  PubMed  CAS  Google Scholar 

  43. Ryan, J. M., Barry, F., Murphy, J. M., & Mahon, B. P. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clinical and Experimental Immunology, 149(2), 353–363.

    Article  PubMed  CAS  Google Scholar 

  44. Ren, G., Zhang, L., Zhao, X., et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2(2), 141–150.

    Article  PubMed  CAS  Google Scholar 

  45. Almeida, C. R., Vasconcelos, D. P., Goncalves, R. M., & Barbosa, M. A. (2012). Enhanced mesenchymal stromal cell recruitment via natural killer cells by incorporation of inflammatory signals in biomaterials. Journal of the Royal Society, Interface, 9(67), 261–271.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Subprograma Inncorpora-Torres Quevedo 2011 (PTQ-11-04554). Thanks to V Alvarez and V Crisostomo for critical review and helpful comments. There is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Disclosure of Potential Conflicts of Interest

The authors declare no conflict of interest or financial interests.

Author information

Authors and Affiliations

  1. Stem Cell Therapy Unit, Minimally Invasive Surgery Centre Jesus Uson, Ctra. N-521 Km 41,8, 10071, Caceres, Spain

    Javier G. Casado & F. M. Sanchez-Margallo

  2. Immunology Unit, Department of Physiology, University of Extremadura, Caceres, Spain

    R. Tarazona

Authors
  1. Javier G. Casado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Tarazona
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. M. Sanchez-Margallo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier G. Casado.

Additional information

Author Contribution Summary

Javier G Casado, R Tarazona and FM Sanchez-Margallo equally contributed in manuscript writing, preparation and discussion.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casado, J.G., Tarazona, R. & Sanchez-Margallo, F.M. NK and MSCs Crosstalk: The Sense of Immunomodulation and Their Sensitivity. Stem Cell Rev and Rep 9, 184–189 (2013). https://doi.org/10.1007/s12015-013-9430-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12015-013-9430-y

Keywords

Search

Navigation